Predicting Persistent Postconcussive Problems in Pediatrics (5P) (5P)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01873287|
Recruitment Status : Completed
First Posted : June 10, 2013
Last Update Posted : January 28, 2016
Concussion, a mild traumatic injury common in children and adolescents, is a complex pathophysiological process affecting the brain. The lay press is inundated with reports of tragic consequences of concussion, and children are not immune.
Persistent postconcussive symptoms (PCS) is defined as the persistence of somatic, cognitive, physical, psychological or behavioural changes lasting more than one month following injury. PCS significantly impacts children and their family's quality of life through school absenteeism, depressed mood and loss of activities.
Validated, easy-to-use prognosticators do not exist for clinicians to identify children at highest risk for PCS. As a result,physicians cannot accurately inform children and parents whether they should expect longer symptoms, nor initiate pharmacotherapy or other management to reduce the occurrence or severity of PCS.
The investigators objective is to derive and validate a clinical prediction rule for the development of PCS in children and adolescents presenting to the emergency department (ED) following acute head injury. The investigators have three aims: (1) determine PCS incidence at one-month follow-up in children aged 5-17 who sustain a concussion; (2) derive a rule to predict PCS from variables present in the history and physical examination; and, (3) assess the accuracy, reliability and acceptability of the prediction rule in a subsequent cohort. Using a prospective, multicentre study at nine large Canadian pediatric EDs, the investigators will recruit the largest prospective epidemiological cohort of children with concussions in the literature.
This work will provide rigorous evidence to determine PCS incidence in children and its impact on quality of life. The results will enable clinicians to identify children at highest risk for PCS, optimize treatment and provide families with realistic anticipatory guidance. This study will also establish a strong and vital evidence base to advance concussion research.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||3063 participants|
|Official Title:||Predicting Persistent Postconcussive Problems in Pediatrics: A Clinical Prediction Rule Derivation and Validation Study|
|Study Start Date :||August 2013|
|Actual Primary Completion Date :||June 2015|
|Actual Study Completion Date :||June 2015|
- Proportion of children who have PCS at one-month follow-up. [ Time Frame: 1 month ]The primary outcome is the proportion of children aged 5 - 17 years who have PCS at one-month follow-up. A PCS case is defined as an increase from pre-concussion baseline of three or more symptoms on the validated PCSI at one-month (consistent with the ICD-10 definition of PCS).
- Pediatric Quality of Life Inventory [ Time Frame: 1 month ]The PedsQL™ is a reliable and valid measure of health-related quality of life in healthy children and adolescents and those with acute and/or chronic health conditions. Parent versions exist for children aged 2 to 18 years (in 4 age groups) and child versions for those aged 5 and over. The inventory covers four domains: physical, emotional, social and school. This secondary outcome measure will be used to determine the impact of PCS on quality of life on patients and families.
- Neuropsychological Evaluation [ Time Frame: 1 month and 3 month ]A separate battery of neuropsychological assessment measures will be administered to those children who choose to participate in this arm of the study. This battery includes measures of intelligence, language, visual-spatial/motor functions, attention, memory/working memory, executive functioning, academic achievement, as well as behavioural/socioemotional functioning.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01873287
|Stollery Children's Hospital|
|Edmonton, Alberta, Canada|
|Children's Hospital of Winnipeg|
|Winnipeg, Manitoba, Canada|
|Canada, Nova Scotia|
|IWK Health Sciences Centre|
|Halifax, Nova Scotia, Canada|
|Alberta Children's Hospital|
|Calgary, Ontario, Canada|
|Children's Hospital of Western Ontario|
|London, Ontario, Canada|
|Children's Hospital of Eastern Ontario|
|Ottawa, Ontario, Canada, K1H 8L1|
|The Hospital for Sick Children|
|Toronto, Ontario, Canada|
|Montreal, Quebec, Canada|
|Montreal Children's Hospital|
|Montreal, Quebec, Canada|
|Principal Investigator:||Roger L Zemek, MD||CHEO|